CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SWK Holdings Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SWK Holdings Corp
5956 Sherry Lane, Suite 650
Phone: (214) 217-7253p:214 217-7253 DALLAS, TX  75225  United States Ticker: SWKHSWKH
Business Summary
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
7372 Prepackaged software
6159 Miscellaneous business credit institutions
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Laurie L.Dotter 62 1/1/2023 2/9/2022
President, Chief Executive Officer, Interim Chief Financial and Accounting officer Joe D.Staggs 42 2/13/2024 9/1/2022
Director MarcusPennington 36 5/17/2021 5/17/2021
Independent Director Jerry G.Albright 64 3/15/2023 3/15/2023
Independent Director Robert K.Hatcher 60 2/15/2022 2/15/2022

Subsidiaries
Business Name Address City State/Province Country
Enteris BioPharma, Inc. 83 Fulton Street Boonton NJ United States

Business Names
Business Name
Enteris BioPharma, Inc.
KANA Software, Inc.
SWK Advisors LLC
5 additional Business Names available in full report.

General Information
Number of Employees: 23 (As of 12/31/2023)
Outstanding Shares: 12,497,109 (As of 3/14/2024)
Shareholders: 88
Stock Exchange: NASD
Federal Tax Id: 770435679
Fax Number: (972) 687-7255
Email Address: info@kana.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024